

Final Study Report

Study Title: A phase II Investigation of Pembrolizumab (Keytruda) in combination with radiation and an immune modulatory cocktail in patients with cervical and uterine cancer (PRIMMO trial)

EudraCT number: 2016-001569-97

Eudamed number: N/A

Study protocol code: PRIMMO AGO/2016/004

ClinicalTrial.gov identifier: NCT03192059

Sponsor: UZ Ghent

National Coordinator/ Coordinating Investigator: Prof. dr. Hannelore Denys

Funder: MSD and Nutrisan provided material support by delivering study drugs pembrolizumab and curcumin, respectively, free of charge. Monetary support was provided by Kom op Tegen Kanker (Stand up to Cancer, the Flemish cancer society); de Nationale Loterij; and Anticancer Fund. Neither the funders nor the providers of medication had any role in study design (except Anticancer Fund), data collection, data analysis, data interpretation, or in the writing of the report.

Date of report: 13th October 2022

Note: For additional information, I refer to our open access paper on which this report has been based (De Jaeghere, et al. Cancer Immunology, Immunotherapy 2022).

Name and signature Sponsor:

A handwritten signature in blue ink, appearing to read 'Hannelore Denys', is written over a dotted line. The signature is stylized and cursive.

Date signature Sponsor: 10 NOV 2022